Search

Your search keyword '"Jones, Roy B."' showing total 442 results
Start Over Author "Jones, Roy B."
442 results on '"Jones, Roy B."'

51. Biokinetics of yttrium-90-labeled huBrE-3 monoclonal antibody

Author

Johnson, Timothy K., Cole, William, Quaife, Robert A., Lear, James L., Ceriani, Roberto L., Jones, Roy B., and Cagnoni, Pablo J.

Subjects
Radioimmunotherapy -- Physiological aspects, Cancer -- Radioimmunotherapy, Monoclonal antibodies -- Physiological aspects, Breast cancer -- Radiotherapy, Health
Published
2002

55. Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation

Author

Olson, Amanda L., primary, Lin, Ruitao, additional, Bdaiwi, Mustafa, additional, Thall, Peter F, additional, Rafei, Hind, additional, Kaur, Indreshpal, additional, Li, Li, additional, Abueg, Glorette, additional, Timmons, Melissa, additional, Chemaly, Roy, additional, Marin, David, additional, Alousi, Amin M., additional, Ahmed, Sairah, additional, Ciurea, Stefan O., additional, Hosing, Chitra, additional, Kebriaei, Partow, additional, Jones, Roy B, additional, Andersson, Borje S, additional, Oran, Betul, additional, Abuddayeh, Ala, additional, Popat, Uday, additional, Champlin, Richard E., additional, Shpall, Elizabeth J., additional, and Rezvani, Katayoun, additional

Published
2019
Full Text
View/download PDF

56. A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS

Author

Champlin, Richard E., primary, Popat, Uday, primary, Oran, Betul, primary, Ciurea, Stefan O., primary, Kebriaei, Partow, primary, Alousi, Amin M., primary, Alatrash, Gheath, primary, Bashir, Qaiser, primary, Khouri, Issa F., primary, Hosing, Chitra, primary, Anderlini, Paolo, primary, Jones, Roy B, primary, Marin, David, primary, Mehta, Rohtesh, primary, Nieto, Yago, primary, Olson, Amanda L., primary, Qazilbash, Muzaffar H., primary, Rezvani, Katy, primary, Shpall, Elizabeth J., primary, Chen, Julianne, primary, Rondon, Gabriela, primary, McMullin, Becky, primary, Al Jahdhami, Vivian P, primary, Kawedia, Jitesh, primary, Valdez, Benigno C., primary, Ma, Junsheng, primary, Thall, Peter F, primary, and Andersson, Borje S, primary

Published
2019
Full Text
View/download PDF

58. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS

Author

Alatrash, Gheath, primary, Kidwell, Kelly M., additional, Thall, Peter F., additional, Di Stasi, Antonio, additional, Chen, Julianne, additional, Zope, Madhushree, additional, Crain, Alyssa K., additional, Champlin, Richard E., additional, Popat, Uday, additional, Shpall, Elizabeth J., additional, Jones, Roy B., additional, and Andersson, Borje S., additional

Published
2018
Full Text
View/download PDF

60. Transplantation of ex vivo expanded cord blood

Author

Shpall, Elizabeth J, Quinones, Ralph, Giller, Roger, Zeng, Chan, Baron, Anna E, Jones, Roy B, Bearman, Scott I, Nieto, Yago, Freed, Brian, Madinger, Nancy, Hogan, Christopher J, Slat-Vasquez, Vicki, Russell, Peggy, Blunk, Betsy, Schissel, Deborah, Hild, Elaine, Malcolm, Janet, Ward, William, and McNiece, Ian K

Published
2002
Full Text
View/download PDF

63. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine

Author

Jones, Roy B., Matthes, Steven, Shpall, Elizabeth J., Fisher, James H., Stemmer, Salomon M., Dufton, Christopher, Stephens, Janet K., and Bearman, Scott I.

Subjects
Pharmacokinetics -- Research, Chemotherapy, Combination -- Adverse and side effects, Carmustine -- Adverse and side effects, Lungs -- Injuries, Health
Abstract

Background: Therapy with high-dose cyclophosphamide, cisplatin, and carmustine (BCNU) plus autologous bone marrow transplantation has been extensively studied as treatment for patients with stage II or III breast cancer who have a 70% or greater risk of developing metastatic disease. This therapy is being used in a cooperative intergroup phase III clinical trial. In the cyclophosphamide-cisplatin-BCNU regimen, cyclophosphamide and BCNU, but not cisplatin, have been reported to cause acute lung injury, suggesting that either cyclophosphamide or BCNU may contribute to this injury. Purpose: The purpose of this study was to analyze clinical and pharmacokinetic data from our ongoing phase II trials and to determine whether there is an association between BCNU pharmacokinetics and acute lung injury following cyclophosphamide-cisplatin-BCNU therapy. Methods: We performed a retrospective study of 38 patients treated following induction therapy or relapse, 29 with stage II-IV breast cancer and nine with intermediate and high-grade stage III-IV non-Hodgkin's lymphoma. These patients received therapy with cyclophosphamide at a dose of 1875 [mu]g/[m.sup.2] daily as a 1-hour intravenous infusion for 3 days, cisplatin at 55 mg/[m.sup.2] per day as a 72-hour continuous intravenous infusion, and BCNU at 600 mg/[m.sup.2] as a 2-hour infusion immediately following completion of the cisplatin infusion. Data from analysis of blood samples were used to calculate pharmacokinetic parameters for BCNU, and acute lung injury was determined on the basis of pulmonary function test results and histologic examination of lung biopsy specimens. Results: Our analysis showed that 20 (53%) of the 38 patients developed pulmonary injury following treatment. Twelve (60%) of the 20 had values for area under the curve (AUC) for BCNU concentration x time that exceeded 600 ([mu]g/mL) x minute, whereas only two (11%) of the 18 without pulmonary injury had values above this level (P

Published
1993

65. Status of high-dose chemotherapy for breast cancer: A review

Author

Nieto, Yago, Champlin, Richard E., Wingard, John R., Vredenburgh, James J., Elias, Anthony D., Richardson, Paul, Glaspy, John, Jones, Roy B., Stiff, Patrick J., Bearman, Scott I., Cagnoni, Pablo J., McSweeney, Peter A., LeMaistre, C.Fred, Pecora, Andrew L., and Shpall, Elizabeth J.

Published
2000
Full Text
View/download PDF

67. The Duke AFM program: intensive induction chemotherapy for metastatic breast cancer

Author

Jones, Roy B., Shpall, Elizabeth J., Shogan, Jeffrey, Affronti, Mary Lou, Coniglio, David, Hart, Lowell, Halperin, Edward, Iglehart, J. Dirk, Moore, Joseph, Gockerman, Jon, Bast, Robert C., and Peters, William P.

Subjects
Fluorouracil -- Health aspects, Doxorubicin -- Health aspects, Methotrexate -- Health aspects, Breast cancer, Health
Abstract

Metastatic breast cancer is a malignancy of the breast tissue associated with the spreading of cancer cells to other body sites. Because this disease is not considered curable, most treatment methods are designed only to reduce symptoms and disease severity. An intensive dose schedule of the anticancer agent doxorubicin produced complete remission for longer than 18 months in only three of 26 patients treated and caused toxic effects on the heart. Treatment with the anticancer agents cyclophosphamide, cisplatin, and carmustine with bone marrow support to maintain marrow function produced complete remission in 15 percent of patients for longer than 18 months. Because relapses occurred in tissues with a large amount of tumor, it was suggested that a reduction in tumor size may improve responses to treatment. The effectiveness of the combined use of these treatment approaches was assessed in 45 patients with metastatic breast cancer. The drug regimen consisted of doxorubicin, 5-fluorouracil, methotrexate, and a method to maintain bone marrow function called 'folinic acid (or leucovorin) rescue' (AFM), and was designed to shrink the tumor rapidly and extensively before treating patients with high doses of alkylating-type anticancer agents and bone marrow support. Ninety-one percent of the patients responded to treatment, and complete clinical response was achieved in 38 percent after an average of 70 days of treatment. These findings show that AFM is effective in producing remission in patients with metastatic breast cancer. However, the considerable toxicity of the regimen must be considered in its routine use for breast cancer. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

68. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia

Author

Lin, Paul, primary, Veltri, Lauren Westfall, additional, Rezvani, Katy, additional, Oran, Betul, additional, Ahmed, Sairah, additional, Alatrash, Gheath, additional, Mehta, Rohtesh S., additional, Rondon, Gabriela, additional, Kebriaei, Partow, additional, Popat, Uday, additional, Nieto, Yago, additional, Hosing, Chitra, additional, Jones, Roy B, additional, Qazilbash, Muzaffar H., additional, Khouri, Issa F., additional, Shpall, Elizabeth J., additional, Champlin, Richard E, additional, and Marin, David, additional

Published
2018
Full Text
View/download PDF

69. Development and validation of a risk assessment tool for symptomatic BKV infection.

Author

Abudayyeh, Ala, primary, Abdelrahim, Maen, additional, Lin, Heather Y., additional, Page, Valda D, additional, Rondon, Gabriela, additional, Andersson, Borje, additional, Martinez, Charles, additional, Tarrand, Jeffery, additional, Kontoyiannis, Dimitrios P, additional, Marin, David, additional, Gaber, A.Osama, additional, Oran, Betul, additional, Chemaly, Roy, additional, Olson, Amanda Leigh, additional, Jones, Roy B., additional, Popat, Uday R., additional, Shpall, Elizabeth J., additional, and Rezvani, Katayoun, additional

Published
2018
Full Text
View/download PDF

72. Double Epigenetic Modulation of High-Dose Chemotherapy With Azacitidine and Vorinostat for Patients With Refractory or Poor-Risk Relapsed Lymphoma

Author

Nieto, Yago, Valdez, Benigno C., Thall, Peter F., Jones, Roy B., Wei, Wei, Myers, Alan, Hosing, Chitra, Ahmed, Sairah, Popat, Uday, Shpall, Elizabeth J., Qazilbash, Muzaffar, Gulbis, Alison, Anderlini, Paolo, Shah, Nina, Bashir, Qaiser, Alousi, Amin, Oki, Yasuhiro, Fanale, Michelle, Dabaja, Bouthaina, Pinnix, Chelsea, Champlin, Richard, and Andersson, Borje S.

Subjects
Adult, Male, Adolescent, Lymphoma, Hydroxamic Acids, Deoxycytidine, Article, Epigenesis, Genetic, Young Adult, Antineoplastic Combined Chemotherapy Protocols, Humans, Child, Busulfan, Melphalan, Aged, Neoplasm Staging, Vorinostat, Middle Aged, Prognosis, Gemcitabine, Survival Rate, Drug Resistance, Neoplasm, Azacitidine, Female, Neoplasm Recurrence, Local, Follow-Up Studies
Abstract

More active high-dose chemotherapy (HDC) regimens are needed for refractory lymphomas. The authors previously combined infusional gemcitabine with busulfan and melphalan (Gem/Bu/Mel) pursuing DNA damage repair inhibition. Subsequently, they combined Gem/Bu/Mel with vorinostat, which facilitates chemotherapy access to DNA. The resulting regimen was safe and synergistic. However, vorinostat induced DNA methyltransferase up-regulation, which could be preclinically abrogated by azacitidine, increasing tumor-cell kill. Those observations led to a clinical combination of azacitidine with vorinostat/Gem/Bu/Mel.Patients ages 12 to 65 years with refractory or poor-risk relapsed lymphomas were eligible. They received intravenous azacitidine on days -11 through -3 at doses from 15 to 35 mg/m(2) daily (dose levels 1-3), followed by oral vorinostat (1000 mg once daily on days -11 through -3), gemcitabine (2775 mg/m(2) over 4.5 × 2), busulfan (at an area under the receiver operating characteristic curve of 4000 daily × 4), and melphalan (60 mg/m(2) × 2). Patients who had tumors that were positive for CD20 (cluster of differentiation 20; B-lymphocyte antigen) received rituximab on day -9.In total, 60 patients were enrolled, including 26 with diffuse large B-cell lymphoma (DLBCL) (10 double hit/double expressors), 21 with Hodgkin lymphoma, 8 with T-cell lymphoma, and 5 with other B-cell lymphomas. The median patient age was 41 years (range, 16-65 years), patients had received a median of 3 prior lines of chemotherapy (range, 2-7 lines of chemotherapy); and 32% of tumors were positive on positron emission tomography studies at the time of HDC. Two patients died from treatment complications (respiratory syncytial virus pneumonia and sepsis, respectively). The maximum tolerated dose of azacitidine was encountered at dose level 1 (15 mg/m(2) daily). The toxicity profile (mainly mucositis and dermatitis) was manageable and was identical to that of vorinostat/Gem/Bu/Mel. Neutrophils and platelets engrafted promptly. At a median follow-up of 15 months (range, 8-27 months), the event-free and overall survival rates were 65% and 77%, respectively, among patients with DLBCL; 76% and 95%, respectively, among patients with Hodgkin lymphoma; and 88% for both among patients with T-cell lymphoma.Double epigenetic modulation of Gem/Bu/Mel with azacitidine/vorinostat is feasible and highly active in patients with refractory/poor-risk relapsed lymphomas, warranting further evaluation. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2680-2688. © 2016 American Cancer Society.

Published
2016

73. Better survival with fludarabine and timed sequential busulfan regimen in older patients with AML/MDS.

Author

Popat, Uday R., primary, Saliba, Rima, additional, Oran, Betul, additional, Ahmed, Sairah, additional, Alousi, Amin Majid, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra, additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Marin, David, additional, Nieto, Yago, additional, Olson, Amanda Leigh, additional, Qazilbash, Muzaffar H., additional, Rezvani, Katayoun, additional, Valdez, Ben, additional, Jones, Roy B., additional, Shpall, Elizabeth J., additional, Andersson, Borje, additional, and Champlin, Richard E., additional

Published
2017
Full Text
View/download PDF

74. Infusional gemcitabine + docetaxel/melphalan/carboplatin (GemDMC) ± bevacizumab (BEV) as an effective high-dose chemotherapy (HDC) regimen for refractory of poor-risk relapsed germ-cell tumors (GCT).

Author

Nieto, Yago, primary, Tu, Shi-Ming, additional, Campbell, Matthew T., additional, Bassett, Roland, additional, Tannir, Nizar M., additional, Ward, John Francis, additional, Hofstetter, Wayne Lewis, additional, Jones, Roy B., additional, Andersson, Borje, additional, Gulbis, Alison M, additional, Ledesma, Celina, additional, Timmons, Melissa, additional, Trapp, Michelle, additional, Champlin, Richard E., additional, and Pagliaro, Lance C., additional

Published
2017
Full Text
View/download PDF

75. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem Cell Transplant (ASCT) in Hodgkin's Lymphoma Patients at High Risk of Post-Transplant Recurrence—Comparison with a Concurrent Matched Cohort

Author

Nieto, Yago, primary, Bassett, Roland, additional, Ahmed, Sairah, additional, Anderlini, Paolo, additional, Hosing, Chitra M., additional, Popat, Uday R., additional, Andersson, Borje S., additional, Valdez, Ben C., additional, Shpall, Elizabeth J., additional, Qazilbash, Muzaffar H., additional, Kebriaei, Partow, additional, Alousi, Amin M., additional, Guillermo, Maria, additional, Oki, Yasuhiro, additional, Fanale, Michelle A., additional, Hagemeister, Frederick, additional, Dabaja, Bouthaina, additional, Pinnix, Chelsea, additional, Milgrom, Sarah, additional, Champlin, Richard E., additional, and Jones, Roy B., additional

Published
2017
Full Text
View/download PDF

78. Myocardial ischemia associated with high-dose carmustine infusion

Author

Kanj, Souha S., Sharara, Ala I., Shpall, Elizabeth J., Jones, Roy B., and Peters, William P.

Subjects
Ischemia -- Causes of, Carmustine -- Adverse and side effects, Health
Abstract

Carmustine, also called BCNU, is a powerful anticancer agent which is used for both solid tumors and lymphomas. BCNU has serious side effects, however, including bone marrow suppression, liver toxicity, lung disease, and progressive kidney failure. Recently, attempts to use high doses of BCNU have been combined with autologous bone marrow transplantation. In this procedure, bone marrow taken from the patient is replaced later to supplant the bone marrow that has been crippled by the chemotherapeutic treatment. While this procedure permits the use of higher doses of BCNU, it also results in high rates of other side effects besides bone marrow suppression. While many of the side effects have been well studied, researchers have now found that myocardial ischemia is a side effect which has been previously overlooked. Myocardial ischemia is the inadequate supply of oxygen to the heart muscle resulting from obstructed blood flow. This same phenomenon is common in the form of angina pectoris, and, if the oxygen deprivation is severe enough, may result in a heart attack. The condition most often results from disease of the blood vessels supplying the heart. Three patients receiving infusions of BCNU developed chest pain and racing heart beats during or immediately after the infusion. Electrocardiograms (ECGs) taken of the three cancer patients revealed physiological changes indicative of myocardial ischemia. The oldest of the three patients was 41, and none had previous histories of cardiovascular disease. Angina pectoris is normally treated with drugs which relax the blood vessels to the heart; this treatment proved effective in these cancer patients as well. Myocardial ischemia is known to be a side effect of 5-fluorouracil, which is unrelated in molecular structure to BCNU. Although the cause of the myocardial ischemia in patients treated with high-dose BCNU is not understood, these cases illustrate that this side effect must be considered as a possibility in patients receiving this treatment. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

80. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma

Author

Nieto, Yago, primary, Valdez, Benigno C., additional, Thall, Peter F., additional, Jones, Roy B., additional, Wei, Wei, additional, Myers, Alan, additional, Hosing, Chitra, additional, Ahmed, Sairah, additional, Popat, Uday, additional, Shpall, Elizabeth J., additional, Qazilbash, Muzaffar, additional, Gulbis, Alison, additional, Anderlini, Paolo, additional, Shah, Nina, additional, Bashir, Qaiser, additional, Alousi, Amin, additional, Oki, Yasuhiro, additional, Fanale, Michelle, additional, Dabaja, Bouthaina, additional, Pinnix, Chelsea, additional, Champlin, Richard, additional, and Andersson, Borje S., additional

Published
2016
Full Text
View/download PDF

81. Myeloablative Timed Sequential Busulfan is Safe and Appears Promising in Older Patients with AML/MDS

Author

Popat, Uday R., primary, Lyons, Genevieve, additional, Bassett, Roland, additional, Chen, Julianne, additional, Valdez, Ben C., additional, Kawedia, Jitesh D., additional, Ahmed, Sairah, additional, Alousi, Amin M., additional, Anderlini, Paolo, additional, Bashier, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra, additional, Jones, Roy B., additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Marin, David, additional, Nieto, Yago, additional, Olson, Amanda, additional, Oran, Betul, additional, Parmar, Simrit, additional, Patel, Krina, additional, Qazilbash, Muzaffar H., additional, Rezvani, Katy, additional, Shah, Nina, additional, Shpall, Elizabeth J., additional, Andersson, Borje S., additional, and Champlin, Richard E., additional

Published
2016
Full Text
View/download PDF

83. Comparison of High-Dose Gemcitabine, Busulfan and Melphalan (GEM/BU/MEL) and BEAM in Concurrent Patient Cohorts with Mature T-CELL NON-Hodgkin's Lymphoma (T-NHL) Receiving an Autologous Stem Cell Transplantation (ASCT)

Author

Nieto, Yago, primary, Bassett, Roland, additional, Hosing, Chitra, additional, Jones, Roy B., additional, Valdez, Ben C., additional, Kingham, Ashley, additional, Ahmed, Sairah, additional, Alousi, Amin M., additional, Anderlini, Paolo, additional, Popat, Uday R., additional, Qazilbash, Muzaffar H., additional, Shpall, Elizabeth J., additional, Kebriaei, Partow, additional, Brammer, Jonathan E., additional, Oki, Yasuhiro, additional, Fanale, Michelle A., additional, Maadani, Farzaneh, additional, Rondon, Gabriela, additional, Champlin, Richard E., additional, and Andersson, Borje S., additional

Published
2016
Full Text
View/download PDF

85. Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas

Author

Nieto, Yago, Thall, Peter F, Valdez, Benigno C, Ma, Junsheng, Timmons, Melissa, Trapp, Michelle, Ahmed, Sairah, Shpall, Elizabeth J, Jones, Roy B, Hosing, Chitra, Anderlini, Paolo, Popat, Uday, Qazilbash, Muzaffar H., Alousi, Amin, Gulbis, Alison M, Ledesma, Celina, Champlin, Richard E., and Andersson, Borje S

Published
2017
Full Text
View/download PDF

88. Maintenance Therapy with Low-Dose Azacitidine after Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed AML or MDS: a Dose and Schedule Finding Study

Author

de Lima, Marcos, Giralt, Sergio, Thall, Peter F., de Padua Silva, Leandro, Jones, Roy B., Komanduri, Krishna, Braun, Thomas M., Nguyen, Hoang Q., Champlin, Richard, and Garcia-Manero, Guillermo

Subjects
Adult, Male, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, DNA Methylation, Middle Aged, Article, Disease-Free Survival, Drug Administration Schedule, Leukemia, Myeloid, Acute, Recurrence, Myelodysplastic Syndromes, Azacitidine, Humans, Transplantation, Homologous, Female, Aged
Abstract

Recurrence is a major cause of treatment failure after allogeneic transplantation for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), and treatment options are very limited. Azacitidine is a DNA methyltransferase inhibitor with activity in myeloid disease. The authors hypothesized that low-dose azacitidine administered after transplant would reduce recurrence rates, and conducted a study to determine a safe dose/schedule combination.Forty-five high-risk patients were treated. Median age was 60 years; median number of comorbidities was 3; 67% were not in remission. By using a Bayesian adaptive method to determine the best dose/schedule combination based on time to toxicity, the authors investigated combinations of 5 daily azacitidine doses, 8, 16, 24, 32, and 40 mg/m2, and 4 schedules: 1, 2, 3, or 4 cycles, each with 5 days of drug and 25 days of rest. Cycle 1 started on Day +40.Reversible thrombocytopenia was the dose-limiting toxicity. The optimal combination was 32 mg/m2 given for 4 cycles. Median follow-up was 20.5 months. One-year event-free and overall survival were 58% and 77%, justifying further studies to estimate long-term clinical benefit. No dose significantly affected DNA global methylation.Azacitidine at 32 mg/m2 given for 5 days is safe and can be administered after allogeneic transplant for at least 4 cycles to heavily pretreated AML/MDS patients. The trial also suggested that this treatment may prolong event-free and overall survival, and that more cycles may be associated with greater benefit.

Published
2010

89. Allogeneic transplantation for myelofibrosis: Final analysis of a prospective study after a median follow up of 5 years.

Author

Popat, Uday R., primary, Bassett, Roland L., additional, Chen, Julianne, additional, Alousi, Amin Majid, additional, Anderlini, Paolo, additional, Ciurea, Stefan O., additional, Hosing, Chitra, additional, Jones, Roy B., additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Konoplev, Sergej, additional, De Lima, Marcos J.G., additional, Nieto, Yago, additional, Oran, Betul, additional, Qazilbash, Muzaffar H., additional, Rondon, Gabriela, additional, Shpall, Elizabeth J., additional, Verstovsek, Srdan, additional, Andersson, Borje, additional, and Champlin, Richard E., additional

Published
2015
Full Text
View/download PDF

90. Ex-Utero Plus in Utero Collection of Umbilical Cord Blood (CB) for Banking Yields Higher Total Nucleated Cell Counts (TNC) Compared to Either Procedure Alone

Author

Hosing, Chitra, primary, Munsell, Mark, additional, Armitage, Sue, additional, Sadeghi, Tara, additional, Rezvani, Katy, additional, Oran, Betul, additional, Marin, David, additional, Dworsky, Suzanne, additional, Popat, Uday R., additional, Wilson, Jeffrey, additional, Alousi, Amin M., additional, Shah, Nina, additional, Olson, Amanda, additional, Jones, Roy B., additional, Kebriaei, Partow, additional, Qazilbash, Muzaffar H., additional, Parmar, Simrit, additional, McNiece, Ian, additional, Champlin, Richard E., additional, and Shpall, Elizabeth J., additional

Published
2015
Full Text
View/download PDF

91. Cytogenetics and Blast Count Determine Transplant Outcomes in Advanced AML

Author

Popat, Uday R., primary, Saliba, Rima, additional, Oran, Betul, additional, Chen, Julianne, additional, Alousi, Amin M., additional, Ahmed, Sairah, additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra, additional, Jones, Roy B., additional, Kebriaei, Partow, additional, Khouri, Issa F., additional, Nieto, Yago L., additional, Olson, Amanda, additional, Parmar, Simrit, additional, Shah, Nina, additional, Shpall, Elizabeth J., additional, Qazilbash, Muzaffar H., additional, Andersson, Borje S., additional, and Champlin, Richard E., additional

Published
2015
Full Text
View/download PDF

92. 286 - Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem Cell Transplant (ASCT) in Hodgkin's Lymphoma Patients at High Risk of Post-Transplant Recurrence—Comparison with a Concurrent Matched Cohort

Author

Nieto, Yago, Bassett, Roland, Ahmed, Sairah, Anderlini, Paolo, Hosing, Chitra M., Popat, Uday R., Andersson, Borje S., Valdez, Ben C., Shpall, Elizabeth J., Qazilbash, Muzaffar H., Kebriaei, Partow, Alousi, Amin M., Guillermo, Maria, Oki, Yasuhiro, Fanale, Michelle A., Hagemeister, Frederick, Dabaja, Bouthaina, Pinnix, Chelsea, Milgrom, Sarah, Champlin, Richard E., and Jones, Roy B.

Published
2017
Full Text
View/download PDF

94. Clofarabine ± Fludarabine with IV Busulfan and Allogeneic Stem Cell Transplantation for Advanced Myeloid Leukemia (ML) and MDS

Author

Chu, Diem, primary, Valdez, Ben C., additional, Fox, Patricia S., additional, Thall, Peter, additional, Worth, Laura, additional, Popat, Uday R., additional, Jones, Roy B., additional, Shpall, Elizabeth J., additional, Hosing, Chitra, additional, Alousi, Amin M., additional, Rondon, Gabriela, additional, Kebriaei, Partow, additional, Champlin, Richard E., additional, and Andersson, Borje S., additional

Published
2014
Full Text
View/download PDF

96. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblatic Leukemia (ALL) With First Complete Remission (CR)

Author

Oran, Betul, primary, Poon, Michelle, additional, Chen, Julianne, additional, Rondon, Gabriela, additional, Ahmed, Sairah, additional, Andersson, Borje S., additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Hosing, Chitra M., additional, Parmar, Simrit, additional, Qazilbash, Muzaffar H., additional, Popat, Uday R, additional, Nieto, Yago, additional, Alousi, Amin, additional, Jones, Roy B, additional, Rezvani, Katy, additional, de Lima, Marcos, additional, Shpall, Elizabeth J, additional, Champlin, Richard E, additional, and Kebriaei, Partow, additional

Published
2013
Full Text
View/download PDF

97. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma

Author

Nieto, Yago, primary, Shah, Nina, additional, Popat, Uday R, additional, Jones, Roy B, additional, Bashir, Qaiser, additional, Bassett, Rolland, additional, Valdez, Benigno C., additional, Andersson, Borje S, additional, Parmar, Simrit, additional, Orlowski, Robert Z., additional, Shah, Jatin J., additional, Thomas, Sheeba K., additional, Wang, Michael, additional, Champlin, Richard E, additional, and Qazilbash, Muzaffar, additional

Published
2013
Full Text
View/download PDF

98. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas

Author

Nieto, Yago, primary, Thall, Peter F, additional, Valdez, Benigno C., additional, Hosing, Chitra M, additional, Ahmed, Sairah, additional, Jones, Roy B, additional, Shah, Nina, additional, Anderlini, Paolo, additional, Qazilbash, Muzaffar H., additional, Popat, Uday R, additional, Bashir, Qaiser, additional, Shpall, Elizabeth J, additional, Alousi, Amin, additional, Kebriaei, Partow, additional, Fox, Patricia, additional, Bassett, Rolland, additional, Chancoco, Christina, additional, Oki, Yasuhiro, additional, Fanale, Michelle A., additional, Fowler, Nathan, additional, Hagemeister, Frederick, additional, Romaguera, Jorge E, additional, Champlin, Richard E, additional, and Andersson, Borje S., additional

Published
2013
Full Text
View/download PDF

99. Pure Red Cell Aplasia In Major ABO Mismatched Allogeneic Hematopoietic Cell Transplantation Is Associated With Severe Pancytopenia

Author

Aung, Fleur M., primary, Lichtiger, Benjamin, additional, Alousi, Amin, additional, Ahmed, Sairah, additional, Anderlini, Paolo, additional, Andersson, Borje S., additional, Bashir, Qaiser, additional, Ciurea, Stefan O., additional, Jones, Roy B, additional, Kebriaei, Partow, additional, Nieto, Yago, additional, Oran, Betul, additional, Parmar, Simrit, additional, Qazilbash, Muzaffar H., additional, Shah, Nina, additional, Khouri, Issa, additional, Shpall, Elizabeth J, additional, Champlin, Richard E, additional, and Popat, Uday R, additional

Published
2013
Full Text
View/download PDF

100. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant

Author

Ahmed, Sairah, primary, Di Stasi, Antonio, additional, Shpall, Elizabeth J., additional, Khouri, Issa F., additional, Alousi, Amin M., additional, Ciurea, Stefan O., additional, Bashir, Qaiser, additional, Qazilbash, Muzaffar, additional, Jones, Roy B., additional, Nieto, Yago, additional, Parmar, Simrit, additional, Kebriaei, Partow, additional, Shah, Nina, additional, Rezvani, Katy, additional, Hosing, Chitra M, additional, Oran, Betul, additional, Andreeff, Michael, additional, Anderlini, Paolo, additional, Andersson, Borje S, additional, Champlin, Richard E, additional, and Popat, Uday, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results